Intrinsic value of HealthSouth - HLS

Previous Close

$43.29

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$43.29

 
Intrinsic value

$65.15

 
Up/down potential

+50%

 
Rating

str. buy

 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of HLS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 3.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  17.01
  8.10
  7.79
  7.51
  7.26
  7.03
  6.83
  6.65
  6.48
  6.33
  6.20
  6.08
  5.97
  5.88
  5.79
  5.71
  5.64
  5.57
  5.52
  5.47
  5.42
  5.38
  5.34
  5.31
  5.27
  5.25
  5.22
  5.20
  5.18
  5.16
  5.15
Revenue, $m
  3,646
  3,941
  4,248
  4,567
  4,899
  5,244
  5,602
  5,974
  6,361
  6,764
  7,184
  7,621
  8,076
  8,550
  9,045
  9,562
  10,101
  10,664
  11,252
  11,867
  12,510
  13,183
  13,887
  14,624
  15,395
  16,203
  17,049
  17,935
  18,865
  19,838
  20,859
Variable operating expenses, $m
 
  3,063
  3,286
  3,518
  3,760
  4,011
  4,272
  4,543
  4,825
  5,118
  5,424
  5,549
  5,880
  6,226
  6,586
  6,962
  7,355
  7,765
  8,193
  8,641
  9,109
  9,599
  10,112
  10,648
  11,210
  11,798
  12,414
  13,060
  13,736
  14,445
  15,189
Fixed operating expenses, $m
 
  165
  169
  173
  178
  182
  187
  191
  196
  201
  206
  211
  217
  222
  227
  233
  239
  245
  251
  257
  264
  270
  277
  284
  291
  298
  306
  314
  321
  329
  338
Total operating expenses, $m
  3,005
  3,228
  3,455
  3,691
  3,938
  4,193
  4,459
  4,734
  5,021
  5,319
  5,630
  5,760
  6,097
  6,448
  6,813
  7,195
  7,594
  8,010
  8,444
  8,898
  9,373
  9,869
  10,389
  10,932
  11,501
  12,096
  12,720
  13,374
  14,057
  14,774
  15,527
Operating income, $m
  641
  714
  793
  876
  961
  1,051
  1,143
  1,240
  1,341
  1,445
  1,554
  1,860
  1,979
  2,103
  2,232
  2,366
  2,507
  2,654
  2,808
  2,969
  3,137
  3,313
  3,498
  3,691
  3,894
  4,106
  4,329
  4,562
  4,807
  5,064
  5,333
EBITDA, $m
  814
  996
  1,083
  1,173
  1,266
  1,363
  1,464
  1,569
  1,678
  1,792
  1,911
  2,034
  2,163
  2,298
  2,438
  2,584
  2,738
  2,897
  3,065
  3,240
  3,423
  3,614
  3,815
  4,025
  4,245
  4,476
  4,718
  4,972
  5,238
  5,517
  5,809
Interest expense (income), $m
  164
  158
  174
  192
  210
  229
  248
  269
  290
  312
  335
  359
  383
  409
  436
  464
  494
  524
  556
  590
  624
  661
  699
  739
  781
  825
  871
  919
  969
  1,022
  1,077
Earnings before tax, $m
  482
  556
  619
  684
  751
  822
  895
  971
  1,051
  1,133
  1,219
  1,502
  1,596
  1,693
  1,795
  1,902
  2,013
  2,130
  2,252
  2,379
  2,513
  2,652
  2,799
  2,952
  3,113
  3,281
  3,458
  3,644
  3,838
  4,042
  4,256
Tax expense, $m
  164
  150
  167
  185
  203
  222
  242
  262
  284
  306
  329
  406
  431
  457
  485
  514
  544
  575
  608
  642
  678
  716
  756
  797
  840
  886
  934
  984
  1,036
  1,091
  1,149
Net income, $m
  248
  406
  452
  499
  549
  600
  653
  709
  767
  827
  890
  1,096
  1,165
  1,236
  1,311
  1,388
  1,470
  1,555
  1,644
  1,737
  1,834
  1,936
  2,043
  2,155
  2,272
  2,395
  2,524
  2,660
  2,802
  2,951
  3,107

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  41
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  4,682
  5,014
  5,405
  5,811
  6,233
  6,671
  7,127
  7,601
  8,093
  8,606
  9,140
  9,696
  10,275
  10,878
  11,508
  12,165
  12,851
  13,567
  14,316
  15,098
  15,916
  16,772
  17,668
  18,605
  19,586
  20,614
  21,691
  22,819
  24,001
  25,240
  26,539
Adjusted assets (=assets-cash), $m
  4,641
  5,014
  5,405
  5,811
  6,233
  6,671
  7,127
  7,601
  8,093
  8,606
  9,140
  9,696
  10,275
  10,878
  11,508
  12,165
  12,851
  13,567
  14,316
  15,098
  15,916
  16,772
  17,668
  18,605
  19,586
  20,614
  21,691
  22,819
  24,001
  25,240
  26,539
Revenue / Adjusted assets
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
  0.786
Average production assets, $m
  1,766
  1,908
  2,056
  2,211
  2,371
  2,538
  2,711
  2,892
  3,079
  3,274
  3,477
  3,688
  3,909
  4,138
  4,378
  4,628
  4,889
  5,161
  5,446
  5,744
  6,055
  6,381
  6,721
  7,078
  7,451
  7,842
  8,252
  8,681
  9,130
  9,602
  10,096
Working capital, $m
  179
  189
  204
  219
  235
  252
  269
  287
  305
  325
  345
  366
  388
  410
  434
  459
  485
  512
  540
  570
  600
  633
  667
  702
  739
  778
  818
  861
  905
  952
  1,001
Total debt, $m
  3,016
  3,292
  3,621
  3,963
  4,318
  4,687
  5,071
  5,470
  5,885
  6,316
  6,766
  7,234
  7,721
  8,230
  8,760
  9,313
  9,890
  10,494
  11,124
  11,783
  12,472
  13,192
  13,946
  14,735
  15,562
  16,427
  17,334
  18,283
  19,279
  20,322
  21,415
Total liabilities, $m
  3,946
  4,222
  4,551
  4,893
  5,248
  5,617
  6,001
  6,400
  6,815
  7,246
  7,696
  8,164
  8,651
  9,160
  9,690
  10,243
  10,820
  11,424
  12,054
  12,713
  13,402
  14,122
  14,876
  15,665
  16,492
  17,357
  18,264
  19,213
  20,209
  21,252
  22,345
Total equity, $m
  736
  792
  854
  918
  985
  1,054
  1,126
  1,201
  1,279
  1,360
  1,444
  1,532
  1,623
  1,719
  1,818
  1,922
  2,030
  2,144
  2,262
  2,386
  2,515
  2,650
  2,791
  2,940
  3,095
  3,257
  3,427
  3,605
  3,792
  3,988
  4,193
Total liabilities and equity, $m
  4,682
  5,014
  5,405
  5,811
  6,233
  6,671
  7,127
  7,601
  8,094
  8,606
  9,140
  9,696
  10,274
  10,879
  11,508
  12,165
  12,850
  13,568
  14,316
  15,099
  15,917
  16,772
  17,667
  18,605
  19,587
  20,614
  21,691
  22,818
  24,001
  25,240
  26,538
Debt-to-equity ratio
  4.098
  4.160
  4.240
  4.320
  4.380
  4.450
  4.500
  4.550
  4.600
  4.650
  4.690
  4.720
  4.760
  4.790
  4.820
  4.850
  4.870
  4.900
  4.920
  4.940
  4.960
  4.980
  5.000
  5.010
  5.030
  5.040
  5.060
  5.070
  5.080
  5.100
  5.110
Adjusted equity ratio
  0.150
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158
  0.158

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  248
  406
  452
  499
  549
  600
  653
  709
  767
  827
  890
  1,096
  1,165
  1,236
  1,311
  1,388
  1,470
  1,555
  1,644
  1,737
  1,834
  1,936
  2,043
  2,155
  2,272
  2,395
  2,524
  2,660
  2,802
  2,951
  3,107
Depreciation, amort., depletion, $m
  173
  283
  290
  297
  305
  312
  321
  329
  338
  347
  357
  174
  184
  195
  207
  218
  231
  243
  257
  271
  286
  301
  317
  334
  351
  370
  389
  409
  431
  453
  476
Funds from operations, $m
  480
  688
  741
  796
  853
  912
  974
  1,038
  1,105
  1,174
  1,247
  1,270
  1,349
  1,431
  1,517
  1,607
  1,700
  1,798
  1,901
  2,008
  2,120
  2,237
  2,360
  2,489
  2,624
  2,765
  2,914
  3,069
  3,232
  3,403
  3,583
Change in working capital, $m
  -126
  14
  15
  15
  16
  17
  17
  18
  19
  19
  20
  21
  22
  23
  24
  25
  26
  27
  28
  30
  31
  32
  34
  35
  37
  39
  41
  43
  45
  47
  49
Cash from operations, $m
  606
  711
  727
  781
  837
  896
  957
  1,020
  1,086
  1,155
  1,227
  1,249
  1,327
  1,409
  1,493
  1,582
  1,674
  1,771
  1,872
  1,978
  2,089
  2,205
  2,326
  2,454
  2,587
  2,727
  2,873
  3,027
  3,188
  3,357
  3,534
Maintenance CAPEX, $m
  0
  -83
  -90
  -97
  -104
  -112
  -120
  -128
  -136
  -145
  -154
  -164
  -174
  -184
  -195
  -207
  -218
  -231
  -243
  -257
  -271
  -286
  -301
  -317
  -334
  -351
  -370
  -389
  -409
  -431
  -453
New CAPEX, $m
  -203
  -142
  -149
  -154
  -160
  -167
  -173
  -180
  -187
  -195
  -203
  -211
  -220
  -230
  -240
  -250
  -261
  -273
  -285
  -298
  -311
  -326
  -341
  -357
  -373
  -391
  -410
  -429
  -450
  -471
  -494
Cash from investing activities, $m
  -245
  -225
  -239
  -251
  -264
  -279
  -293
  -308
  -323
  -340
  -357
  -375
  -394
  -414
  -435
  -457
  -479
  -504
  -528
  -555
  -582
  -612
  -642
  -674
  -707
  -742
  -780
  -818
  -859
  -902
  -947
Free cash flow, $m
  361
  486
  488
  529
  572
  617
  664
  712
  762
  815
  869
  874
  933
  994
  1,059
  1,125
  1,195
  1,268
  1,344
  1,424
  1,507
  1,594
  1,685
  1,780
  1,880
  1,984
  2,094
  2,208
  2,329
  2,455
  2,587
Issuance/(repayment) of debt, $m
  -193
  313
  329
  342
  355
  369
  384
  399
  415
  432
  449
  468
  488
  508
  530
  553
  578
  603
  630
  659
  689
  721
  754
  789
  826
  865
  906
  950
  995
  1,043
  1,094
Issuance/(repurchase) of shares, $m
  -66
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -298
  313
  329
  342
  355
  369
  384
  399
  415
  432
  449
  468
  488
  508
  530
  553
  578
  603
  630
  659
  689
  721
  754
  789
  826
  865
  906
  950
  995
  1,043
  1,094
Total cash flow (excl. dividends), $m
  63
  800
  817
  871
  928
  986
  1,047
  1,111
  1,177
  1,246
  1,319
  1,342
  1,421
  1,503
  1,589
  1,679
  1,773
  1,871
  1,974
  2,082
  2,196
  2,314
  2,439
  2,569
  2,706
  2,850
  3,000
  3,158
  3,324
  3,498
  3,681
Retained Cash Flow (-), $m
  -125
  -60
  -62
  -64
  -67
  -69
  -72
  -75
  -78
  -81
  -84
  -88
  -91
  -95
  -99
  -104
  -108
  -113
  -118
  -124
  -129
  -135
  -141
  -148
  -155
  -162
  -170
  -178
  -187
  -196
  -205
Prev. year cash balance distribution, $m
 
  4
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  743
  755
  807
  861
  917
  975
  1,036
  1,099
  1,165
  1,234
  1,254
  1,329
  1,407
  1,489
  1,575
  1,664
  1,758
  1,856
  1,959
  2,066
  2,179
  2,297
  2,421
  2,551
  2,687
  2,830
  2,980
  3,137
  3,302
  3,475
Discount rate, %
 
  10.30
  10.82
  11.36
  11.92
  12.52
  13.15
  13.80
  14.49
  15.22
  15.98
  16.78
  17.62
  18.50
  19.42
  20.39
  21.41
  22.48
  23.61
  24.79
  26.03
  27.33
  28.70
  30.13
  31.64
  33.22
  34.88
  36.62
  38.45
  40.38
  42.40
PV of cash for distribution, $m
 
  674
  615
  584
  549
  508
  465
  419
  372
  326
  280
  228
  190
  155
  124
  97
  75
  56
  41
  29
  20
  14
  9
  6
  3
  2
  1
  1
  0
  0
  0
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

HealthSouth Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates through two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on both an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. As of December 31, 2016, it operated 123 inpatient rehabilitation hospitals; and managed 5 inpatient rehabilitation units through management contracts. The Home Health and Hospice segment provides home health and hospice services in 223 locations across 25 states primarily in the Southeast, Oklahoma, and Texas. Its home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care, which comprise skilled nursing, medical social work, and home health aide services, as well as physical, occupational, and speech therapy. This segmentÂ’s hospice services comprise in-home services to terminally ill patients and their families to address patientsÂ’ physical needs, including pain control and symptom management, and to provide emotional and spiritual support. The company was founded in 1983 and is headquartered in Birmingham, Alabama.

FINANCIAL RATIOS  of  HealthSouth (HLS)

Valuation Ratios
P/E Ratio 15.5
Price to Sales 1.1
Price to Book 5.2
Price to Tangible Book
Price to Cash Flow 6.4
Price to Free Cash Flow 9.6
Growth Rates
Sales Growth Rate 17%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 29.3%
Cap. Spend. - 3 Yr. Gr. Rate -1.3%
Financial Strength
Quick Ratio 1
Current Ratio 0.1
LT Debt to Equity 404.8%
Total Debt to Equity 409.8%
Interest Coverage 4
Management Effectiveness
Return On Assets 7.7%
Ret/ On Assets - 3 Yr. Avg. 8%
Return On Total Capital 6.6%
Ret/ On T. Cap. - 3 Yr. Avg. 7.3%
Return On Equity 36.8%
Return On Equity - 3 Yr. Avg. 37.4%
Asset Turnover 0.8
Profitability Ratios
Gross Margin 96.2%
Gross Margin - 3 Yr. Avg. 95.8%
EBITDA Margin 22.5%
EBITDA Margin - 3 Yr. Avg. 22.9%
Operating Margin 17.6%
Oper. Margin - 3 Yr. Avg. 17.9%
Pre-Tax Margin 13.2%
Pre-Tax Margin - 3 Yr. Avg. 14.1%
Net Profit Margin 6.8%
Net Profit Margin - 3 Yr. Avg. 7.3%
Effective Tax Rate 34%
Eff/ Tax Rate - 3 Yr. Avg. 32.9%
Payout Ratio 33.9%

HLS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the HLS stock intrinsic value calculation we used $3646 million for the last fiscal year's total revenue generated by HealthSouth. The default revenue input number comes from 2016 income statement of HealthSouth. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our HLS stock valuation model: a) initial revenue growth rate of 8.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 10.3%, whose default value for HLS is calculated based on our internal credit rating of HealthSouth, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of HealthSouth.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of HLS stock the variable cost ratio is equal to 78.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $161 million in the base year in the intrinsic value calculation for HLS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.3% for HealthSouth.

Corporate tax rate of 27% is the nominal tax rate for HealthSouth. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the HLS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for HLS are equal to 48.4%.

Life of production assets of 21.2 years is the average useful life of capital assets used in HealthSouth operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for HLS is equal to 4.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $736 million for HealthSouth - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 89.699 million for HealthSouth is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of HealthSouth at the current share price and the inputted number of shares is $3.9 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
SEM Select Medical 13.65 25.57  str.buy
MYOK MyoKardia 12.65 167.62  str.buy
CYH Community Heal 8.24 25.87  str.buy

COMPANY NEWS

▶ Soon-to-open Pearland rehab hospital names CEO   [Mar-27-17 01:30PM  at bizjournals.com]
▶ HealthSouth to Hold Annual Stockholder Meeting   [Mar-24-17 11:53AM  PR Newswire]
▶ HealthSouth Declares Dividend on Common Stock   [Feb-17-17 10:09AM  PR Newswire]
▶ Royal Cup makes CFO hire   [Jan-17-17 03:40PM  at bizjournals.com]
▶ How HealthSouth Corp (HLS) Stacks Up Against Its Peers   [Nov-30-16 03:34PM  at Insider Monkey]
▶ Check out plans for HealthSouth's new office   [Nov-10-16 05:05PM  at bizjournals.com]
▶ HealthSouth Corp Set to Join the S&P Midcap 400   [Nov-01-16 06:09PM  PR Newswire]
▶ [$$] HealthSouth CEO to Step Down at Year's End   [04:50PM  at The Wall Street Journal]
▶ HealthSouth CEO Grinney to retire, successor named   [04:46PM  at bizjournals.com]
▶ HealthSouth posts strong 2Q performance   [Aug-02-16 02:15PM  at bizjournals.com]
▶ Local firms make $111M deal for Texas properties   [Jul-21-16 01:50PM  at bizjournals.com]
▶ BJC partners with HealthSouth on rehab hospital   [Jul-05-16 12:35PM  at bizjournals.com]
Stock chart of HLS Financial statements of HLS
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.